Elicio Therapeutics (NASDAQ:ELTX) Coverage Initiated by Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH started coverage on shares of Elicio Therapeutics (NASDAQ:ELTX) in a research note published on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating and a $20.00 target price on the stock.

Several other brokerages have also commented on ELTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Monday, December 29th. HC Wainwright increased their price objective on shares of Elicio Therapeutics from $13.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Rodman & Renshaw raised shares of Elicio Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Finally, Wall Street Zen raised shares of Elicio Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Elicio Therapeutics Stock Performance

Shares of Elicio Therapeutics stock opened at $11.78 on Wednesday. The firm has a market capitalization of $216.75 million, a P/E ratio of -4.50 and a beta of 1.11. The company has a quick ratio of 2.38, a current ratio of 2.38 and a debt-to-equity ratio of 5.75. The company has a 50 day moving average price of $10.56 and a 200 day moving average price of $9.46. Elicio Therapeutics has a 52 week low of $4.70 and a 52 week high of $14.93.

Elicio Therapeutics (NASDAQ:ELTX) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.02). Sell-side analysts expect that Elicio Therapeutics will post -3.89 EPS for the current year.

Hedge Funds Weigh In On Elicio Therapeutics

A number of institutional investors have recently bought and sold shares of ELTX. Royal Bank of Canada purchased a new position in Elicio Therapeutics during the 1st quarter worth approximately $225,000. Jane Street Group LLC purchased a new position in Elicio Therapeutics during the 1st quarter worth approximately $92,000. Geode Capital Management LLC raised its position in Elicio Therapeutics by 56.0% during the 2nd quarter. Geode Capital Management LLC now owns 120,831 shares of the company’s stock worth $933,000 after buying an additional 43,364 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Elicio Therapeutics during the 2nd quarter worth approximately $46,000. Finally, Vanguard Group Inc. raised its position in Elicio Therapeutics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 473,859 shares of the company’s stock worth $5,184,000 after buying an additional 19,240 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Elicio Therapeutics Company Profile

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.